US Patent

US9447104 — Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds

Method of Use · Assigned to Array Biopharma Inc · Expires 2029-10-21 · 3y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds, such as Larotrectinib sulfate, for various conditions in mammals.

USPTO Abstract

Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2470`	—	larotrectinib-sulfate
`U-2470`	—	larotrectinib-sulfate
`U-2470`	—	larotrectinib-sulfate

Patent Metadata

Patent number: US9447104
Jurisdiction: US
Classification: Method of Use
Expires: 2029-10-21
Drug substance claim: No
Drug product claim: No
Assignee: Array Biopharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.